Literature DB >> 15190035

Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance.

Darrin J Bast1, Abed Athamna, Carla L Duncan, Joyce C S de Azavedo, Donald E Low, Galia Rahav, David Farrell, Ethan Rubinstein.   

Abstract

OBJECTIVES: To identify and characterize the mechanisms of high-level fluoroquinolone resistance in two strains of Bacillus anthracis following serial passage in increasing concentrations of fluoroquinolones.
METHODS: Fluoroquinolone-resistant isolates of the Sterne and Russian Anthrax Vaccine STi strains were obtained following serial passage in the presence of increasing concentrations of four different fluoroquinolones. The quinolone-resistance-determining regions of the type II topoisomerase genes from the resistant strains were amplified by PCR and characterized by DNA sequence analysis. The MICs in the presence and absence of reserpine were determined using broth microdilution as a means of detecting active efflux.
RESULTS: Single and double amino acid substitutions in the GyrA (Ser-85-Leu; Glu-89-Arg/Gly/Lys) and GrlA (Ser-81-Tyr; Val-96-Ala; Asn-70-Lys) were most common. A single amino acid substitution in GyrB (Asp-430-Asn) was also identified. Efflux only applied to isolates selected for by either levofloxacin or ofloxacin.
CONCLUSIONS: Specific amino acid substitutions in the type II topoisomerase enzymes significantly contributed to the development of high-level fluoroquinolone resistance in B. anthracis. However, notable differences between the strains and the drugs tested were identified including the role of efflux and the numbers and types of mutations identified.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15190035     DOI: 10.1093/jac/dkh294

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.

Authors:  Katie J Aldred; Sylvia A McPherson; Pengfei Wang; Robert J Kerns; David E Graves; Charles L Turnbough; Neil Osheroff
Journal:  Biochemistry       Date:  2011-12-16       Impact factor: 3.162

2.  Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.

Authors:  Katie J Aldred; Heidi A Schwanz; Gangqin Li; Sylvia A McPherson; Charles L Turnbough; Robert J Kerns; Neil Osheroff
Journal:  ACS Chem Biol       Date:  2013-09-30       Impact factor: 5.100

Review 3.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

Review 4.  The Bacillus cereus Group: Bacillus Species with Pathogenic Potential.

Authors:  Monika Ehling-Schulz; Didier Lereclus; Theresa M Koehler
Journal:  Microbiol Spectr       Date:  2019-05

5.  Activity of quinolone CP-115,955 against bacterial and human type II topoisomerases is mediated by different interactions.

Authors:  Katie J Aldred; Heidi A Schwanz; Gangqin Li; Benjamin H Williamson; Sylvia A McPherson; Charles L Turnbough; Robert J Kerns; Neil Osheroff
Journal:  Biochemistry       Date:  2015-01-23       Impact factor: 3.162

6.  Genomewide screening for novel genetic variations associated with ciprofloxacin resistance in Bacillus anthracis.

Authors:  Masakuni Serizawa; Tsuyoshi Sekizuka; Akiko Okutani; Satomi Banno; Tetsutaro Sata; Satoshi Inoue; Makoto Kuroda
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

7.  Evaluation of Combination Drug Therapy for Treatment of Antibiotic-Resistant Inhalation Anthrax in a Murine Model.

Authors:  H S Heine; S V Shadomy; A E Boyer; L Chuvala; R Riggins; A Kesterson; J Myrick; J Craig; M G Candela; J R Barr; K Hendricks; W A Bower; H Walke; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

8.  Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.

Authors:  Arnold Louie; Brian D VanScoy; David L Brown; Robert W Kulawy; Henry S Heine; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

9.  Molecular identification of hemolymph-associated symbiotic bacteria in red imported fire ant larvae.

Authors:  Stanley Gunawan; Danielle M Tufts; Blake R Bextine
Journal:  Curr Microbiol       Date:  2008-09-16       Impact factor: 2.188

10.  Structural and functional analysis of two glutamate racemase isozymes from Bacillus anthracis and implications for inhibitor design.

Authors:  Melissa May; Shahila Mehboob; Debbie C Mulhearn; Zhiqiang Wang; Huidong Yu; Gregory R J Thatcher; Bernard D Santarsiero; Michael E Johnson; Andrew D Mesecar
Journal:  J Mol Biol       Date:  2007-06-04       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.